In partnership with

Good day, 360!

As always, here’s some top movers today. For our latest hot stock alerts, simply text the word RAGE to 1-(888) 404-5747 📲. Be the most “in-the-know” trader on the Street!

FOCUS LIST🔎

QURE – Up over 50% in the pre-market after announcing alignment with FDA on key elements of accelerated approval pathway for AMT-130 in Huntington’s Disease

TRNR – Up over 50% in pre after announcing it had regained full compliance with Nasdaq continued listing standards

NAMS – Up over 60% in pre after announcing positive Topline Data from Pivotal Phase 3 BROADWAY clinical trial evaluating Obicetrapib in patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

*sponsored by Autopilot

Invest Alongside Top Politicians And Famous Hedge Fund Managers

HOTLIST🔥

QURE – Up over 50% in the pre-market after announcing alignment with FDA on key elements of accelerated approval pathway for AMT-130 in Huntington’s Disease

uniQure N.V. (QURE) develops treatments for patients suffering from rare and other devastating diseases.

In the pre-market this morning, the company announcedthat it had reached agreement with the U.S. Food and Drug Administration (FDA) on key elements of an Accelerated Approval pathway for AMT-130. 

Highlights include:

~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~

~ FDA agrees that the composite Unified Huntington’s Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval ~

Shares of QURE traded up over 50% in the pre-market in reaction to the news.

The $12 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $13.30, $14, and then the pre-market high at $14.99. Beyond that, $18 and $20 come into play.

Below $12, targets to the downside are $11, $10, $8 and then a gap fill at $7.30. 

TRNR – Up over 50% in pre after announcing it had regained full compliance with Nasdaq continued listing standards

Interactive Strength Inc. (TRNR) is the maker of innovative specialty fitness equipment under the CLMBR and FORME brands.

In the pre-market this morning, the company announced that it had received a letter from the Staff at Nasdaq Listings Qualifications stating that the Company has regained compliance with Listing Rule 5550(a)(2), which specifies rules regarding a minimum bid price of $1.00.

Trent Ward, Co-Founder and CEO of TRNR, stated: 

“We are now in full compliance with Nasdaq continuing listing standards after receiving this most recent letter about bid price, which follows the compliance letter regarding Stockholder’s Equity from a couple weeks ago. We hope we have put these compliance issues behind us permanently and look forward to a long and successful future on Nasdaq.”

The Company also regained compliance with the requirement of having more than 500,000 Publicly Held Shares, as confirmed on November 14 with the filing of the Company’s third quarter 10-Q, which reported 625,067 shares outstanding on that date.

Shares of TRNR traded up over 50% in the pre-market in reaction to the news.

The $3.25 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $3.70, $4, $4.40 and then the pre-market high at $4.78. Beyond that $5 and $6 come into play.

Below $3.25, targets to the downside are $3.15, $3 and then a gap fill at $2.70.

*sponsored by Finance Buzz

Tackle your credit card debt by paying 0% interest until 2026

NAMS – Up over 60% in pre after announcing positive Topline Data from Pivotal Phase 3 BROADWAY clinical trial evaluating Obicetrapib in patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma Company N.V. (NAMS) is a late-stage biopharmaceutical company that develops therapies to enhance patient care in populations with metabolic disease.

In the pre-market this morning, the company announcedpositive topline data from the Company’s Phase 3 BROADWAY clinical trial (NCT05142722) evaluating Obicetrapib in adult patients with established atherosclerotic cardiovascular disease (“ASCVD”) and/or heterozygous familial hypercholesterolemia (“HeFH”), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.

Highlights include:

— Achievedprimary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p<0.0001) —

— 21% observed reduction in major adverse cardiovascular events favoring Obicetrapib at one year –

— Observed to be well-tolerated with safety results comparable to placebo –

Shares of NAMS traded up over 60% in the pre-market in reaction to the news.

The $27.70 area acted as support in the pre-market and will be an important level to watch.

Targets to the upside are $29, $30 and then the pre-market high at $32.23.

Below $27.80, targets to the downside are $26, $25, $24, $22.50, $21 and then $19.50.

MARKET NEWS 📰

Don’t miss out on our MOBILE ALERTS!  We have seen some of these alerts rocket 🚀past the MOON 🌝.  To be first in line for the next one, simply text the word “RAGE” to 1-(888) 404-5747 📲.